Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an agreement with IMP Clinical Supply Services (“IMP”).

Source

Previous articlePT408 – Fireside Project: Harm Reduction Through Free Peer Support
Next articlePsychedelics, The Brain, and the Future of Mental Health